




eu  
european congenital  
cytomegalovirus initiative

**ATHENS**

**OCTOBER  
20-21, 2022**



[ecci2022.com](http://ecci2022.com)





**Day 1. Thursday October 20<sup>th</sup>, 2022**

<b>09.15</b>	Welcome <b>Vana Papaevangelou</b> (Greece)
<b>09.20</b>	ECCI Mission and Activities <b>Ann Vossen</b> (The Netherlands)
<b>09.25</b>	Partnership with ESCV <b>Pamela Vallely</b> (United Kingdom)
<b>09.30-10:00</b>	<b>Plenary session</b> CMV reactivation and reinfection <b>Judy Breuer</b> (United Kingdom)
<b>10:00-11.30</b>	<b>Session 1. Pathogenesis and Disease Burden</b> Chairs: <b>Ann Vossen - Dana Wolf</b> Keynote lectures <ul style="list-style-type: none"> <li><b>10.00</b> Pathophysiology of fetal brain infection <b>Stephane Chavanas</b> (France)</li> <li><b>10.30</b> Disease burden: PI and NPI maternal infection <b>Daniele Lilleri</b> (Italy)</li> <li><b>11.00</b> Oral presentations</li> </ul> <b>OP 01</b> CONGENITAL CMV INFECTION IN FRANCE: THE BURDEN OF SEVERE CASES IN THE ABSENCE OF SYSTEMATIC SCREENING. DATA FROM THE FRENCH "CONGENITAL CMV DECLARATION PLATFORM" OF THE NATIONAL REFERENCE CENTER FOR HERPESVIRUSES. <b>OP 02</b> PRENATAL SCREENING FOR CMV PRIMARY INFECTION IN QUEBEC: A COST-EFFECTIVENESS MODEL <b>OP 03</b> REPLICATION PROPERTIES AND IMMUNOMODULATORY EFFECTS OF HUMAN CYTOMEGALOVIRUS INFECTION IMPACT THE CLINICAL PRESENTATION IN CONGENITAL PATIENTS
<b>11.30-12.00</b>	<b>COFFEE BREAK</b>
<b>12.00-13.30</b>	<b>Session 2. Prognostic factors in pregnancy</b> Chairs: <b>Marianne Leruez-Ville - George Sourvinos</b> Keynote lectures <ul style="list-style-type: none"> <li><b>12.00</b> Prenatal prognostic factors: US and beyond <b>Yves Ville</b> (France)</li> <li><b>12.30</b> Prognostic amniotic fluid biomarkers of congenital CMV severity <b>Dana Wolf</b> (Israel)</li> <li><b>13.00</b> Oral presentations</li> </ul> <b>OP 04</b> PROFILE AND CONCENTRATION OF CYTOKINES FRACTIONS IN AMNIOTIC FLUID OF FETUSES INFECTED WITH CYTOMEGALOVIRUS. <b>OP 05</b> HUMAN CYTOMEGALOVIRUS (HCMV) LONG-TERM SHEDDING AND HCMV-SPECIFIC IMMUNE RESPONSE IN PREGNANT WOMEN WITH PRIMARY HCMV INFECTION <b>OP 06</b> ONE YEAR OF FIRST TRIMESTER UNIVERSAL SCREENING FOR CYTOMEGALOVIRUS AT TWO TERTIARY REFERRAL CENTERS IN BARCELONA (CATALUNYA, SPAIN)



<b>13.30-14.30</b>	<b>LUNCH AND POSTER VIEWING</b>
<b>14.30-16.00</b>	<p><b>Session 3. Diagnosis and treatment in Pregnancy</b>          Chairs: <b>Yves Ville - Georgios Daskalakis</b>          Keynote lectures</p> <ul style="list-style-type: none"> <li>• <b>14.30</b> Diagnosis of maternal infection  <b>Tizianna Lazzarotto</b> (Italy)</li> <li>• <b>15.00</b> Antiviral treatment in pregnancy  <b>Marianne Leruez-Ville</b> (France)</li> <li>• <b>15.30</b> Oral presentations</li> </ul> <p><b>OP 07</b>          NEW THERAPEUTIC PERSPECTIVE IN THE PREVENTION OF CONGENITAL CYTOMEGALOVIRUS INFECTION</p> <p><b>OP 08</b>          NEONATAL AND LONG-TERM OUTCOMES OF INFANTS WITH CONGENITAL CYTOMEGALOVIRUS INFECTION AND NEGATIVE AMNIOCENTESIS</p> <p><b>OP 09</b>          WHAT DOES THE "HALO" SIGN MEAN IN FETAL CYTOMEGALOVIRUS INFECTION?</p>
<b>16.00-16.30</b>	<b>COFFEE BREAK</b>
<b>16.30-17.00</b>	<b>SATELLITE SYMPOSIUM</b>
<b>17.00-17.45</b>	<b>SATELLITE SYMPOSIUM</b>
<b>17.45-19.15</b>	<p><b>Session 4. Primary Prevention and Vaccines</b>          Chairs: <b>Daniele Lilleri - Anastasia Antoniadou</b>          Keynote lectures</p> <ul style="list-style-type: none"> <li>• <b>17.45</b> Primary prevention by maternal education  <b>Chrissie Jones</b> (United Kingdom)</li> <li>• <b>18.15</b> CMV vaccines: an overview  <b>Mark Schleiss</b> (United States of America)</li> <li>• <b>18.45</b> Oral presentations</li> </ul> <p><b>OP 10</b>          WOMEN'S AWARENESS OF CYTOMEGALOVIRUS INFECTION IN PREGNANCY: A SURVEY STUDY</p> <p><b>OP 11</b>          VACCINATION OF YOUNG CHILDREN WITH MODESTLY-PROTECTIVE CYTOMEGALOVIRUS VACCINES MAY EFFECTIVELY PREVENT CONGENITAL INFECTION AT THE POPULATION SCALE</p> <p><b>OP 12</b>          INTERIM RESULTS FROM A PHASE 2, RANDOMIZED, OBSERVER-BLIND, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF AN MRNA-BASED CYTOMEGALOVIRUS VACCINE IN HEALTHY ADULTS</p>
	<b>END OF DAY ONE</b>




**Day 2. Friday October 21<sup>st</sup>, 2022**

<b>09.00-10.30</b>	<p><b>Session 5. Prognostic Markers in neonates</b> Chairs: <b>David Kimberlin - Vana Papaevangelou</b> Keynote lectures</p> <ul style="list-style-type: none"> <li>• <b>09.00</b> cCMVnet: The importance of a European Registry <b>Hermione Lyall</b> (United Kingdom)</li> <li>• <b>09.20</b> Development of a prognostic score <b>Daniel Blazquez-Gamero</b> (Spain)</li> <li>• <b>09.40</b> Neonatal MRI as a prognostic tool. <b>Kachramanoglou Carolina</b> (United Kingdom)</li> <li>• <b>10.00</b> Oral presentations</li> </ul> <p><b>OP 13</b> INFRATENTORIAL IMAGING FINDINGS IN CONGENITAL CMV</p> <p><b>OP 14</b> ISOLATED WHITE MATTER ABNORMALITIES AT BIRTH AS PROGNOSTIC MARKERS IN CONGENITAL CYTOMEGALOVIRUS INFECTION</p> <p><b>OP 15</b> VIROLOGICAL CONTROL OVER TIME IN A COHORT OF SYMPTOMATIC AND ASYMPTOMATIC, TREATED AND UNTREATED CASES OF CONGENITAL CYTOMEGALOVIRUS</p>
<b>10:30-11:15</b>	<b>SATELLITE SYMPOSIUM</b>
<b>11.15-13.00</b>	<p><b>Session 6. Neonatal screening and treatment of neonates and children</b> Chairs: <b>Chrissie Jones - Despoina Gkentzi</b> Keynote lectures</p> <ul style="list-style-type: none"> <li>• <b>11.15</b> Treatment of neonates and children: an overview <b>David Kimberlin</b> (United States of America)</li> <li>• <b>11.45</b> Neonatal screening: translation of research to policy <b>Mark Schleiss</b> (United States of America)</li> <li>• <b>12.15</b> Oral presentations</li> </ul> <p><b>OP 16</b> DIAGNOSTIC ABILITY OF TARGETED AND UNIVERSAL NEONATAL SCREENING FOR cCMV-INFECTION, TO PROVIDE TIMELY DIAGNOSIS OF cCMV-INFECTION ASSOCIATED NEURODEVELOPMENTAL DELAY.</p> <p><b>OP 17</b> COMPARISON OF OVERALL SENSITIVITY AND SPECIFICITY ACROSS DIFFERENT NEWBORN CONGENITAL CYTOMEGALOVIRUS SCREENING ALGORITHMS</p> <p><b>OP 18</b> RISK FACTORS ASSOCIATED WITH SEVERE NEUTROPENIA IN CHILDREN WITH CONGENITAL CYTOMEGALOVIRUS INFECTION TREATED WITH GANCICLOVIR/VALGANCICLOVIR</p>
<b>13:00-14:15</b>	<b>LUNCH AND POSTER VIEWING</b>



<p><b>14.15-15.45</b></p>	<p><b>Session 7. Immunopathology and long-term outcomes</b>          Chairs: <b>Pam Vallely - Hermione Lyall</b>          Keynote lectures</p> <ul style="list-style-type: none"> <li>• <b>14.15</b> cCMV immunology update  <b>Laura Gibson</b> (United States of America)</li> <li>• <b>14.35</b> Long term hearing loss  <b>Ina Foulon</b> (Belgium)</li> <li>• <b>14.55</b> Vestibular and Olfactory nerve dysfunction  <b>Natacha Teissier</b> (France)</li> <li>• <b>15.15</b> Oral presentations</li> </ul> <p><b>OP 19</b>          PROGNOSTIC VALUE OF NEONATAL CLINICAL, RADIOLOGICAL AND BIOLOGICAL MARKERS FOR THE DEVELOPMENT OF NEUROSENSORIAL SEQUELAE IN CHILDREN INFECTED BY CYTOMEGALOVIRUS (CMV) IN UTERO (CYMEPEDIA)</p> <p><b>OP 20</b>          CONGENITAL CMV INFECTION WITHIN THE AUDITORY PATHWAY FROM INNER EAR TO TEMPORAL AUDITORY CORTEX</p> <p><b>OP 21</b>          HEARING LOSS OUTCOMES AT 24 MONTHS IN ASYMPTOMATIC OR MILDLY SYMPTOMATIC CONGENITAL CMV ACCORDING TO TREATMENT GROUP</p>
<p><b>15:45</b></p>	<p><b>CONCLUSIONS - CLOSURE OF CONFERENCE</b></p>



we've been at this  
for ten years

**our mRNA platform is a modern  
approach to medicine**

**but it's just the beginning**

[modernatx.com](https://modernatx.com)

**moderna**  
-----

Simplexa™ Congenital CMV Direct Kit

# Empowering Early Detection for a Healthy Future

Direct detection of cytomegalovirus DNA  
in saliva swab and urine specimens



The quality of treatment starts with diagnosis.





## Early detection for a healthy future

Every pregnant woman is at risk for CMV which can be passed to their baby in utero

- **Long-term affect:**  
1 in 5 newborns infected with congenital cytomegalovirus become permanently disabled.
- **Test to be sure:**  
90% of babies born with congenital CMV appear healthy at birth.
- **Ease of use:**  
Saliva swabs for easy collection and urine

*Ask for Simplexa Congenital  
CMV Direct testing*

[www.molecular.diasorin.com](http://www.molecular.diasorin.com)  
+39 0161 487526 +1 (562) 240-6500



 DiaSorin  
Molecular

The quality of treatment starts with diagnosis.



